fbpx

Clinical Studies

Clinical Studies

If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.
For a comprehensive list of studies, please check clinicaltrials.gov.

tab‐cel® (tabelecleucel)

Phase Trial Number Trial Description
3 NCT03392142 Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab (MATCH)
3 NCT03394365 Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
1/2 NCT03769467 Tabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma
1/2 NCT00002663 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

ATA188

Phase Trial Number Trial Description
1 NCT03283826 Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive Multiple Sclerosis

Requests for Expanded Access

This Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Atara Biotherapeutics will follow when considering requests by licensed physicians for use of Atara’s investigational drugs outside of clinical trials.

Enrollment

For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.